{"id":979758,"date":"2026-07-08T10:25:22","date_gmt":"2026-07-08T14:25:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-levi-korsinsky-2\/"},"modified":"2026-07-08T10:25:22","modified_gmt":"2026-07-08T14:25:22","slug":"lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-levi-korsinsky-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-on-grail-inc-gral-join-class-action-suit-seeking-recovery-contact-levi-korsinsky-2\/","title":{"rendered":"Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n From Optimism to Disillusionment: How Investor Sentiment in Grail Shifted as NHS-Galleri Confidence Crumbled, Costing Shareholders $51.32 Per Share<\/i>\n <\/p>\n

\n NEW YORK<\/span>, July 8, 2026<\/span> \/PRNewswire\/ — Levi & Korsinsky, LLP provides context on investor sentiment surrounding Grail, Inc. (NASDAQ: GRAL) and a pending securities class action filed on behalf of shareholders who purchased securities between May 13, 2025 and February 19, 2026. Find out if you can recover your Grail investment losses<\/a>\u00a0or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a>\u00a0or (212) 363-7500.<\/p>\n

\n

\n \"Levi\n <\/p>\n<\/p><\/div>\n

GRAL shares collapsed 50.55% on February 20, 2026, erasing $51.32 per share in value after the Company disclosed its NHS-Galleri trial failed to achieve its primary endpoint. Investors have until August 4, 2026 to seek lead plaintiff appointment.<\/p>\n

\n The Early Optimism<\/b>\n <\/p>\n

In May 2025, Grail announced positive top-line results from the prevalent screening round of its 140,000-participant NHS-Galleri trial. The Company reported a substantially higher positive predictive value than the 43% observed in its earlier Pathfinder study. Specificity and cancer signal of origin accuracy were described as consistent with prior results. Investors interpreted these announcements as confirmation that Galleri was performing in real-world conditions and that the three-year trial was on track to deliver a statistically significant reduction in late-stage cancers.<\/p>\n

Sentiment grew further when management repeatedly characterized results as “very encouraging” and positioned the mid-2026 readout as “a great calling card” for global market expansion.<\/p>\n

\n The Growing Concerns<\/b>\n <\/p>\n

Despite the positive framing, questions emerged about what investors were not being told. Management repeatedly declined to share detailed data from the first screening round, citing “integrity” of the trial. Analysts pressed for specifics on statistical powering, PPV figures, and stage-shift implications. Each time, the response was to wait for the final readout. This pattern of withholding created a growing information asymmetry: management had reviewed the underlying data internally while shareholders were left with only selectively positive characterizations.<\/p>\n

\n The Breaking Point<\/b>\n <\/p>\n

On February 19, 2026, Grail revealed that the primary endpoint of a statistically significant reduction in Stage III and IV cancers “was not observed.” The Company attributed this failure, in part, to probably needing “a longer follow-up time.” The admission that the three-year trial design was apparently insufficient directly contradicted repeated assurances that the study was powered to deliver a statistically significant result within that timeframe. GRAL shares fell from 101.53 to 50.21 overnight.<\/p>\n

\n The Sentiment Shift<\/b>\n <\/p>\n